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 Abstract  
 
Objective: Repetitive transcranial magnetic stimulation (rTMS) is an approved 
treatment for depression. The clinical relevance of its efficacy is unclear. The 
clinical relevance of findings in the rTMS literature were assessed by translating 
Hamilton Depression Rating Scale (HAMD) data into Clinical Global Impression 
- Improvement scale (CGI-I) scores.  
Method: Electronically searches of MEDLINE, Embase, PsycInfo, Pubmed, and 
Cochrane Central Register of Controlled Trials for RCTs and non-RCT trials on 
rTMS using Hamilton Depression Rating Scale (HAMD). Articles were included if 
published in English before January 2014. We translated HAMD scores into 
nominal CGI-I scores for rTMS for depression and for treatment resistant 
depression (TRD).  
Results: 960 abstracts were retrieved. 63 studies were included yielding 130 
study arms. For depression the mean percentage change for HAMD scores in all 
sham-controlled rTMS treatment arms was 35.63 (SD 16.35) and for sham-rTMS 
23.33 (SD 16.51) For TRD, active rTMS in sham-controlled studies showed a 
mean HAMD percentage reduction of 45.21 (SD 10.94) versus 25.04 (SD 17.55) 
for sham-rTMS. When aggregated scores were translated into notional CGI-I 
scores, for the treatment of depression the notional CGI-I score difference 
between rTMS and sham-rTMS was 0.5 in favour of rTMS; for TRD it was 0.75 in 
favour of rTMS. Differences between rTMS and sham-rTMS were bigger when 
all study arms were combined. 
Conclusion: Whilst rTMS appears to be efficacious for both non-refractory and 
treatment resistant depression, the clinical relevance of its efficacy is doubtful.  
Key words:  
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 Summations: 
 rTMS does have a small demonstrable antidepressant effect. 
 rTMS generates very small improvements when used in the treatment of non- 
refractory depression. 
 The results in treatment resistant depression are somewhat better, but still 
reflect only minimal clinical improvement. 
 
Considerations: 
 The studies are heterogeneous. 
 We could not consider cumulative doses. 
 The method of translating HAMD to CGI scores is an indirect comparison. 
The minimal clinical improvement found on average does not preclude the 
possibility that rTMS can be associated with a reasonable Numbers 
Needed to Treat (NNT). 
 
 Introduction 
 
 
Depressive disorders are common throughout the world. They are the most important 
cause of Years Lost due to Disability (YLD) for men and women in high, middle and 
low income countries (1, 2). Transcranial magnetic stimulation (TMS) was developed 
in the mid-1980s in Sheffield, UK, as a non-invasive brain stimulation tool (3). 
Improvements in electro-technology led to the development of repetitive TMS (rTMS). 
Several neuroimaging studies reported activation changes in medial and dorsolateral 
regions of the prefrontal cortex in unipolar depressed patients (4-7). These were 
proposed as patho-physiological correlates of depressed mental states, as the 
changes reversed after symptom recovery, irrespective of the therapeutic strategy 
used (8-10). From 1995, research groups used rTMS at frequencies between 1 and 25 
Hz to stimulate the dorsolateral prefrontal cortex (DLPFC) of depressed patients (11, 
12). By consensus, stimulation frequencies above 1 Hz are categorized as high-
frequency rTMS, while stimulation frequencies  1 Hz are categorized as low-
frequency rTMS (13). Extended exposure to high- or low-frequency rTMS was found 
to alter cortical excitability in different ways, influenced by basal cortical activity state 
(14).  
 
Since the first experimental antidepressant TMS trial by Höflich and colleagues (15), 
more than 150 studies of rTMS have been published, using various research designs 
and stimulation parameters. They have reported varying results, but most suggest that 
rTMS has an active therapeutic effect in depression. The DLPFC has been the targeted 
region in almost all studies of rTMS treatment of depression. Nonetheless, 
heterogeneity in parameters and study designs are important limiting factors when 
assessing the antidepressant efficacy of rTMS. An influential review by Ridding and 
Rothwell (16) pointed out that the functional mechanisms of rTMS in depression were 
unknown and recommended further basic research in order to develop greater 
precision in rTMS treatment strategies. Another systematic review by Hermann & 
Ebmeier (2006) found no parameters that predicted a favourable treatment response 
for active rTMS in randomized controlled trials (RCTs) (17). Two years later the same 
authors published a meta-analysis of RCTs (18), limiting studies included to those with 
 more than 10 subjects in each group (active and sham rTMS). This showed a 
statistically significant result in favour of active rTMS. In October 2008, the US Federal 
Drug Administration approved rTMS for the treatment of treatment resistant 
depression, and later for major depressive disorder. A review by Schutter in 2009 
concluded “there is a fairly consistent positive statistical effect […] but the clinical 
relevance remains unclear” (19). In 2010, Slotema and colleagues produced the 
largest meta-analysis published thus far, which included 34 RCTs (n = 1383 patients). 
The mean weighted effect size for all included studies comparing rTMS with sham 
treatment was 0·55 (p<·001). Furthermore, rTMS was marginally more efficacious as 
a mono-therapy than as a combined treatment with an antidepressant agent. However, 
they found Electro-Convulsive Treatment (ECT) to be more effective than rTMS when 
used as a comparator (20). In a 2014 review of high frequency rTMS, Berlim and 
colleagues found higher response and remission rates in rTMS compared to sham-
TMS with associated Numbers Needed to Treat of 6 and 8, respectively (21). 
 
Leucht and colleagues have translated changes in HAMD scales into notional scores 
on the Clinical Global Impressions scales, severity and improvement (CGI-S and CGI-
I) (22). The method used for the translation was equi-percentile linking of HAMD-17 
and CGI ratings (23). The method produced a non-linear graph that allows the manual 
extraction of notional CGI-I scores for every point on the HAMD change score scale 
(see Table 1). The method has limitations, but it generates an acceptably robust 
translation. An independent analysis by Furukawa and colleagues using a different 
dataset and a different approach yielded similar results (24). A similar method has 
previously been used to assess the clinical relevance of antipsychotic trial findings 
(25). That study demonstrated that antipsychotic trial findings show improvements of 
limited clinical relevance despite statistically significant results in individual trials for 
most antipsychotics (25). It also showed significant differences in CGI improvement 
scores between antipsychotics. Some reached a CGI change of two points indicating 
that patients were on average “much improved”. A similar efficacy hierarchy between 
drugs emerged in a later network meta-analysis (26).  
 
Table 1 about here 
Aims of the study 
  
Most systematic reviews and meta-analyses show that there is a statistically significant 
superiority of active rTMS over sham treatment in depression, but the clinical relevance 
of these findings remains unclear. We have performed a systematic review of rTMS in 
depression and in treatment resistant depression in order to assess the clinical 
relevance of its reported efficacy.  
 
 
Method 
 
Search strategy and selection criteria: We searched MEDLINE, Embase, PsycInfo, 
Pubmed, and Cochrane Central Register of Controlled Trials for RCTs and non-RCT 
trials of rTMS using the Hamilton Depression Rating Scale (HAMD). The search terms 
were “Transcranial Magnetic Stimulation“ OR “TMS“ OR “rTMS“ OR “Repetitive TMS“ 
OR “Repetitive Transcranial Magnetic Stimulation“ AND “Depression“ OR “Anxiety“ OR 
“Anxiety Disorders“ OR “Depressive Disorder. Abstracts and reports from meetings 
were not included. Only articles published in English up to 15th January 2014 were 
included. 
 
 
Inclusion criteria: 
 
 Participants: human subjects, formal diagnosis of depression irrespective of the 
subtype of depression or the diagnostic criteria used. 
 Intervention: rTMS as mono-therapy or add-on therapy  
 Comparator: any (sham-rTMS, different forms of rTMS or rTMS delivery, ECT) 
 Outcome measures: percentage change in mean Hamilton depression rating 
scale (HAMD/HDRS) score (given directly or calculated from baseline and 
endpoint data)  
 Design: randomised controlled trial (RCT) or non-RCT (such as open-label or 
naturalistic trials).  
 Reporting:  
 o published in a peer reviewed journal  
o sample size for each study arm reported 
o available as electronic or paper full-text.  
 
Exclusion criteria: 
 
 Studies where depression was not the primary diagnosis (for example, panic 
disorder, schizophrenia, obsessive-compulsive disorder, Parkinson Disease, 
dementia, depression after stroke, mania, alcohol related syndrome, insomnia, 
organic depression) 
 Reviews, meta-analyses, insufficient data (e.g. an exact HAMD percentage 
change was impossible to calculate) 
 Studies of adolescents or children 
 Non-standard rTMS (for example, deep TMS or stimulation outside the DLPFC) 
 
Outcome measures were taken from the last reported follow-up point. In cross-over 
trials, only the first treatment episode was included. Where more than one version of 
HAMD was used we assumed that the HAMD-17 had been used, as the original 
translation used HAMD-17 (as we calculated a percentage change from baseline, this 
should not have had an impact on the analysis). 
 
Full text versions of all identified papers were obtained. Data were extracted 
independently by two reviewers (RSS & SVNL). The two databases were compared 
manually, then examined again by a third reviewer (CS-L) and discrepancies corrected 
by reference to the original papers. We excluded duplicate publications (the same 
patients reported in an earlier publication).  
 
 
 
 
CGI-I score analysis of the following comparisons was performed:  
 
 1. Study arms from sham-controlled RCTs (rTMS versus sham-rTMS) 
2. Study arms from all rTMS trials, controlled and uncontrolled 
3. RCTs comparing ECT versus rTMS 
4. Separate analyses were conducted on 1 and 2 for non-refractory depression 
and TRD.  
5. High (above 1 Hz) versus low versus mixed frequency (Hz) rTMS treatment. 
’Mixed frequency’ includes all studies with changing frequency application 
methods. This usually involved switching impulses between high and low 
frequency application. 
 
 
The primary analysis was based on all RCTs that compared rTMS with sham-rTMS 
and provided sufficient data for analysis (HAMD baseline and endpoint scores or 
percentage changes and standard deviations). In a second step we included all 
available rTMS studies in an attempt to analyse whether the results become better for 
rTMS when naturalistic studies are included, as sham-controlled trials often find less 
favourable results for active interventions. Percentage change between baseline and 
follow-up was calculated for each study. A weighted overall change was calculated for 
each study arm. Weighting was based on sample size (n). These values were used to 
calculate a mean percentage change score for each of the study arms being analysed. 
Percentage change gave a standardised measure of change, which allowed results 
from studies that used HAMD-17, 21, and 24 to be combined in the analysis. The 
percentage HAMD change was plotted with CGI-I scores on a graph. In Leucht et al 
(22) a HAMD reduction of 75%-85% (depending on the week) equals a CGI-I score of 
1 (very much improved), a reduction of 50%-60% equals a CGI-I score of 2 (much 
improved), and of 25%-35% equals a CGI-I score of 3 (minimally improved). As the 
exact figures varied somewhat depending on the week of follow-up used in Leucht et 
al. (22), we used week 4 results for our analysis which was most similar to the average 
duration of the studies included (Tables 1 and 2). Translation was conducted manually 
for each point, as the conversion graphs are not linear (22). This allows indirect 
comparisons between the groups to examine the clinical relevance of the findings. 
Formal hypothesis tests were undertaken using the independent sample t-test. As the 
data were aggregated, the test statistics were calculated by hand and compared with 
 the tabulated values at the required significance level and number of degrees of 
freedom. A 5% significance level was applied, consequently p-values are quoted as 
being either <0.05 (statistically significant) or >0.05 (statistically non-significant)   
 
 
Results 
 
The search generated 464 abstracts after excluding duplicates (see figure 1, 
CONSORT chart). After examining the abstracts, full-text versions of 187 papers were 
obtained. Nine papers could not be procured. Three studies were added after hand-
searching previous systematic reviews and meta-analyses for references. A total of 63 
studies were included in the study (27-89). Reasons for exclusion are shown in Figure 
1. The number of stimulation sessions varied between 5 and 30. The length of follow-
up was between 5 days and 24 weeks. The total stimuli received varied between 3,600 
and 90,000 impulses; study sample size varied between 5 and 155.  
 
Figure 1 about here 
 
The 63 studies included (27-89) (see Table 2 for study characteristics) had between 
two and four study arms and yielded 83 separate study arms relating to treatment with 
rTMS. Thirty-two studies were sham-controlled RCTs with sufficient data to be included 
in the primary analysis. By adding comparator sham-rTMS (36 study arms) and ECT 
(5 study arms), a total of 130 study arms were included in the analysis. As some studies 
have more than 2 study arms there were more study arms than the number of studies. 
The studies comprised a total of 3236 participants (2330 for rTMS, 806 for sham-rTMS 
and 100 for ECT). All studies reported baseline HAMD scores that indicated that the 
participants on average reached the threshold for major depression (most studies used 
HAMD 17 or 21; baseline scores were between 22 and 28 depending on the version 
used). Tables 3 and 4 shows the results of the analysis of HAMD scores including 
mean change in HAMD scores in absolute numbers and as percentages, with the 
translation into notional CGI–I scores. It shows the results for non-refractory 
depression and treatment resistant depression (TRD) separately, comparing sham-
rTMS and rTMS.  
  
Looking at sham-controlled RCTs alone first, we found that rTMS was better in both 
diagnostic categories. The finding was statistically significant for non-refractory 
depression (T=-13.85) and for TRD (T=-10.10). The difference in CGI-I scores between 
sham and real TMS was 0.5 for depression and 0.75 for TRD. 
 
When we take all included studies into account (i.e. sham controlled RCTs and all other 
trials) the results remain significant at p<0.05 for depression (T=-19.59) and TRD (T=-
27.74). For depression, rTMS had a CGI-I advantage of 0.6 over sham-TMS, whilst in 
TRD rTMS had a CGI-I advantage of 1.0 over sham-rTMS. By way of comparison, in 
the ECT group the combined mean difference in HAMD scores was 12.58 (SD 6.98) 
with a CGI-I of 2.45 (percentage HAMD reduction: 46.36 (SD 27.47)). In those rTMS 
studies that used ECT as a comparator, ECT was more effective than rTMS, which 
only reached a HAMD percentage reduction of 33.7%. 
 
Tables 3 and 4 about here 
 
Analysis of different rTMS frequencies has to be interpreted with caution. It is 
presented here to exclude potential bias from the inclusion of all frequencies in the 
rTMS versus sham-rTMS analysis above. We found some statistically significant 
differences between frequencies, but the magnitude of the effect was minimal. In terms 
of HAMD percentage change, low frequency was statistically significantly better than 
high frequency (T=-7.21) and mixed frequency (T=-4.17). Furthermore, mixed was 
better than high (T=-5.37). High frequency trials showed a HAMD percentage reduction 
of 40.94% (SD17.57) (47 studies, 52 study arms, 1295 participants, 10.58 absolute 
HAMD score reduction). For low frequency trials the percentage reduction was 46.57% 
(SD 10.77) (15 studies, 20 study arms, 593 participants, 10.70 absolute HAMD score 
reduction). For mixed frequency trials the percentage reduction was 43.56% (SD 
10.44) (7 studies, 13 study arms, 997 participants, 9.97 absolute HAMD score 
reduction).  
 
 
Discussion 
  
As can be seen from Table 3, rTMS has a measurable effect on symptoms in 
depression, reflected by a 35% and 45% reduction of the HAMD score in our primary 
analysis. However, as is the case in antidepressant trials, there is a strong placebo 
effect, as shown by a 22-25% HAMD reduction using sham-rTMS. Whilst rTMS does 
have a demonstrable specific antidepressant effect, this translates into a CGI-I 
reduction of only 0.5 points, which is of highly questionable clinical relevance in the 
routine treatment of depression. The difference between rTMS and sham-rTMS is 
somewhat larger in treatment resistant depression, but even in the most favourable 
analysis, where uncontrolled studies are combined with sham-controlled RCTs, the 
difference only just reaches the threshold of “minimally improved” on the CGI-I. These 
findings create serious doubt over the clinical relevance of the therapeutic effects of 
rTMS.   
 
We have followed the method of our previous review of antipsychotics (25) in using a 
translation of a symptom-rating instrument (HAMD) into a measure of clinical relevance 
(CGI-I scores) to compare rTMS with sham-rTMS and ECT. Our systematic review is 
the largest performed so far. It is the first to report notional CGI-I scores for rTMS. 
When only sham-controlled RCTs are included in the analysis, our results confirm a 
statistically significant superiority of rTMS over sham-TMS in the treatment of both 
depression and TRD. When non-sham-controlled RCTs and non-RCT trials are 
included, the very small advantage of TMS over sham-rTMS in depression and the 
modest advantage of rTMS in TRD remain robust.  
 
How do our findings compare with the rest of literature? In the first meta-analysis 
combining RCTs of DLPFC stimulation in depression, which included five studies, the 
authors found a beneficial effect of active rTMS compared to sham-rTMS, but the 
extent and the duration of the antidepressant effects of rTMS could not be defined (90). 
Burt and colleagues (2002) included 16 trials in their meta-analysis (n = 377 patients) 
and found that the effect of active rTMS was fairly robust from a statistical viewpoint 
(effect sizes: dpooled = 0.67), but they were doubtful about the effect’s clinical 
significance (91). Indeed, a conventional meta-analysis of the RCTs included in our 
review yielded similar results (non-refractory depression: 22 RCTs, n=1488, SMD = 
 0.63 [0.5,0.74], treatment resistant depression: 10 RCTs, n=376, SMD = 0.74 
[0.52,0.95]. Details can be obtained from the authors upon request). Couturier and 
colleagues (2005) used strict methodological inclusion criteria for rTMS studies (only 
six RCTs were included) and came to the conclusion that active rTMS was no different 
to sham-rTMS (92). Lam and colleagues reviewed the efficacy of rTMS for TRD and 
found that active rTMS was significantly superior to sham conditions in producing 
clinical response, with a modest risk difference of 17% (93). Fitzgerald and colleagues 
(2002), however, were less cautious and asserted that rTMS “appears to have 
considerable potential as a therapeutic tool in depression, and perhaps a role in several 
other disorders” (94). 
 
Applying these standards to our results for non-refractory depression, the result is 
statistically significant, and favourable to rTMS. The advantage of rTMS against sham-
rTMS in sham-controlled RCTs is a HAMD percentage change of 12.30% and a CGI-I 
difference of 0.5 points, which would be barely noticeable in clinical practice. This 
advantage remains robust when all trials are included, with 15.04% HAMD reduction 
(CGI: 0.6). However, it is well recognised that naturalistic studies exaggerate effects. 
 
Applying the same standards to TRD, the results are somewhat more favourable. The 
additional percentage HAMD reduction of TMS against sham-rTMS in TRD is 20.17% 
when only sham-controlled RCTs are included in the analysis. We found a CGI-I 
advantage of 0.75. When all trials are included the advantage of rTMS increases to 
24.74%, which equates to a clinically noticeable, but still small effect.  
 
Sham-rTMS achieves HAMD reductions around 22-25% in both non-refractory and 
treatment-resistant depression, indicating a substantial placebo effect which must be 
subtracted to assess the effect of rTMS. Our results suggest that, in terms of clinically 
meaningful change, rTMS leads to minimal improvements when used in the treatment 
of depression.  
 
To put our findings into context, we have looked at the cognitive-behavioural 
psychotherapy (CBT) and antidepressant literatures using similar methods. Cuijpers 
and colleagues found a considerable difference between psychotherapy and any 
 control in their main analysis (95). However, when the meta-analysis was restricted to 
placebo-pill controlled trials, the advantage of psychotherapy for depression over 
placebo-pill was only 2.66 HAMD absolute points (96). 
  
Our group has found 45.21% difference in HAMD percentage change between 
cognitive behavioural therapy arms and waiting list control arms for non-refractory 
depression (CGI-I difference: 1.85). Against treatment-as-usual, the advantage 
reduced to 29.93% or a CGI-I difference of 1.15; against placebo-pill the difference is 
21.64% or a CGI-I difference of 0.85 (97). In a re-analysis of the controversial Kirsch 
paper, the weighted mean improvement was 2.68 absolute HAMD points in drug 
response over placebo (1.8 in the original paper by Kirsch et al) (98). This compares 
to a 3.38 HAMD point reduction for rTMS in depression in our analysis. Most 
antidepressant reviews compare the percentage of responders (normally defined as a 
HAMD reduction above 50%). Mean percentage reductions are rarely reported. 
Placebo and drug responses show large variability between studies but, on average, 
treatment groups show a 16% higher response rate than placebo. Treatment arm 
response rates can be as high as 70% (99). A meta-analysis on ECT showed average 
absolute HAMD score changes of 9.7 in favour of ECT (100). In summary, our findings 
for rTMS are at the lower end of the range for treatments of depression, a number of 
which do not appear to be highly effective by these standards. 
 
We found few important differences between frequencies used, and we would not wish 
to exaggerate the strength of our method in this regard. Slotema did not find a 
difference between frequency regimes (20). More studies are needed to clarify this.  
 
Our study has some limitations. A major limitation is that our method is indirect. We 
planned to include an analysis of reported CGI results, but we were unable to do so as 
CGI is rarely used in rTMS studies. Translation is only validated for HAMD-17, but 
different versions were used in the studies, and correlations between CGI and HAMD 
were moderate in the original publication (22) suggesting high variability.  
 
As is commonly the case in systematic reviews, a large number of studies were 
excluded for a variety of reasons. There is no reason to suppose that the exclusion of 
 studies has created a bias to minimise the clinical effects of rTMS. Furthermore, most 
studies were small, and small studies tend to overestimate effects. We included non-
randomised studies in secondary analyses, because we wished to perform a review 
with broad inclusion criteria rather than reviewing a small number of RCTs with very 
specific inclusion criteria. This procedure was favourable for rTMS, because it is well 
recognised that uncontrolled trials tend to produce larger effects. Whilst this increases 
heterogeneity, in exchange it produces a large sample size. This is a particular strength 
of our review compared to many smaller reviews previously published. We did not, 
however, examine heterogeneity in this study.  
 
Leucht and colleagues have pointed out that their method of converting HAMD (or 
PANSS/BPRS) continuous scores into CGI categorical scores involves the translation 
of psychometrically validated instruments into impressionistic scales using conversion 
graphs that are not perfectly linear (22, 23, 101). The fact that equi-percentile linking 
does not require linearity is an advantage of the method but means that exact 
translations are difficult to calculate. As the method produces global impression scores, 
it measures something different to meta-analyses that focus on effect sizes. It is 
possible for a treatment to achieve statistically significant results and reasonable 
numbers-needed-to-treat in meta-analyses whilst at the same time achieving low CGI-
I scores (102), therefore having little or no clinical relevance for many patients. 
 
The studies we included did not use a consistent definition of TRD. It cannot be 
assumed that TRD in the context of this literature implies severe or long-term 
depression. Furthermore, previous apparent treatment resistance might have been 
due to poor treatment adherence.  
 
We have not examined duration of treatment or cumulative dose as factors affecting 
outcome, but this would be worthwhile in future research. Many studies measure short-
term outcomes. This is a general weakness of the existing literature. We minimised 
this problem by taking the last available follow-up data in each study. We do not believe 
that the limitations of our study invalidate the principle findings.  
 
Table 2 about here 
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TABLES AND FIGURES 
 
Table 1: HAMD to CGI translation (adapted from Leucht et al (22), based on changes 
at 4 week follow-up) 
 
 CGI-I HAMD % 
change 
Interpretation 
1 -84% Very much improved 
2 -59% Much improved 
3 -33% Minimally improved 
4 -9% No change 
5 +8% Minimally worse 
6 +27.5% Much worse 
7 +60% very much worse 
 
 
Table 2: included studies 
Author Design Arms Type of 
rTMS 
Location Frequency Diagnosis Tool Sample 
size 
Length 
of 
study 
HAMD 
version 
Comments 
Abraham – 
2007 (27)  
Non RCT 
trial 
1 High 
frequency 
Left 
DLPFC 
10Hz TRD DSM-
IV 
20 6 
weeks 
HD 21 Subjects were 60 yrs 
or older 
Avery 2006  
(28) 
RCT 2 High 
Frequency 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
35 5 wks HD 17  
   Sham     33 5 wks   
Avery 2008  
(29) 
Non RCT 
extension 
trial 
2 
Extended 
rTMS 
High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
73 9 wks HD 24 
HD17 
Non RCT extension of 
non-responders in an 
RCT 
  Sham 
followed 
by  rTMS 
High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz   85 9 wks  
Bajbouj 2005  
(30) 
Non RCT 
trial 
1 High 
frequency 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
30 2 wks HD 24 Study compared 
motor cortex 
excitability in 
responders versus 
non responders to 
rTMS 
Bakim 2012  
(31) 
RCT 3 80% MT Left 
DLPFC 
20 Hz TRD DSM-
IV 
12 6 wks HD 17  
   110% MT Left 
DLPFC 
20 Hz   11 6 wks   
   Sham rTMS     12 6 wks   
Benadhira 2005  
(32) 
Non RCT 
trial 
1 High 
Frequency 
Left 
DLPFC 
10 Hz TRD NA 11 4 wks NA  
Berlim 2011  
(33) 
Non RCT 1 High 
Frequency 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
15 4 wks HD 24 rTMS was 
augmentation  to 
antidepressant Rx 
Bretlau 2008  
(34) 
RCT 2 rTMS Left 
DLPFC 
8 Hz TRD DSM-
IV 
25 12 wks HD 17  
   Sham rTMS     24 12 wks   
Chen 2013  
(35) 
RCT 2 High 
frequency 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
10 4 wks HD 17  
   Sham rTMS     10 4 wks   
Conca 2002  
(36)  
RCT 3 High + Low 
frequency 
Left + Rt 
DLPFC 
Left 10 Hz 
Right 1 Hz 
TRD ICD 
10 
12 5 days HD 21  
    High + Low 
frequency 
Left 
DLPFC 
10 Hz 
alternate 
with 1 Hz 
  12 5 days   
   High 
Frequency 
Left 
DLPFC 
10 Hz   12 5 days   
Crevits 2005  
(37) 
Non RCT 1 High 
Frequency 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
11 3 wks HD 21  
Dannon 2002  
(38) 
RCT 2 rTMS Left 
DLPFC 
10 Hz Depression DSM-
IV 
21 24 wks HD 17  
   ECT     20 24 wks   
Dolberg 2002  
(39) 
RCT 2 rTMS NA NA Bipolar 
Depression 
NA 10 4 wks  Subjects had bipolar 
depression 
    Sham TMS      10 6 wks  
Fitzgerald 2006  
(40) 
RCT 4 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz TRD MINI 67 4 wks HD 17 High frequency rTMS 
was provided to the 
non responders to the 
Right sided rTMS as 
an extension trial for 
another 4 weeks 
   Low 
frequency 
rTMS 
Right 
DLPFC 
2 Hz  MINI 63 4 wks HD 17  
   High 
frequency 
Left 
DLPFC 
5 Hz  MINI 16 4 wks HD 17  
   High 
Frequency 
Left 
DLPFC 
10 Hz  MINI 14 4 wks HD 17  
Fitzgerald 2009  
(41) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
NA TRD DSM-
IV 
15 4wks NA Stimulation 
parameters were 
calculated at varying 
duration of stimulus 
and intervals  
   Low 
frequency 
rTMS 
Right 
DLPFC 
NA   11 4 wks  
Fitzgerald 2013  
(42) 
RCT 2 Sequential 
Bilateral 
rTMS 
Right 
DLPFC 
followed 
by Left 
DLPFC 
Right 1 Hz 
Left 10 Hz 
TRD MINI 76 4 wks HD 17  
   Priming 
stimulation 
rTMS 
Right 
DLPFC 
Right 6 Hz 
followed by 
1 Hz 
  85 4 wks HD 17  
Fitzgerald 2011  
(43) 
RCT 3 Low 
frequency 
Right 
DLPFC 
1 Hz TRD MINI 71 4 wks HD 17  
   Sequential 
bilateral 
mixed 
Right 
followed 
by Left 
DLPFC 
Right 1 Hz 
followed by 
left 10 Hz 
 MINI 71 4 wks HD 17  
   Sequential 
bilateral low 
frequency  
Right  
followed 
by Left 
DLPFC 
Right 1 Hz 
followed by 
left 1 Hz 
  76    
Fujita 2005  
(44) 
Non RCT 1 Single pulse 
TMS 
Bilateral 
Frontal 
NA Depression DSM-
IV 
23 5 days NA Single pulse TMS was 
administered at 20 
stimuli per session 
Galletly 2012  
(45) 
RCT 2 Spaced 
rTMS 
Left 
DLPFC 
followed 
by right 
Left 10 Hz 
Right 1 Hz 
Depression DSM-
IV 
42 6 wks HD 21  
   Daily rTMS Left 
DLPFC 
Left 10 Hz 
Right 1 Hz 
 DSM-
IV 
35 6 wks HD 21  
 followed 
by right 
Garcia-Toro 
2001  (46) 
RCT 2 rTMS Left 
DLPFC 
20 HZ Depression DSM-
IV 
17 4 wks HD 21  
   Sham rTMS     18 4 wks   
Garcia-Toro 
2006  (47) 
RCT 3 Bilateral 
rTMS 
Left 
DLPFC 
followed 
by right 
Left 20 Hz 
Right 1 Hz 
TRD DSM-
IV 
10 4 wks HD 21  
   Sham TMS     10    
   SPECT 
guided rTMS 
Different 
locations 
20 Hz to 
lowactivity 
area 
1 Hz to 
High 
activity 
area 
  10    
George 1997  
(48) 
RCT 2 High 
frequency 
Left 
DLPFC 
20 Hz depression DSM-
IV 
7 2 wks HD 21  
   Sham     7 2 wks   
George 2000  
(49) 
RCT 3 High 
Frequency 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
10 2 wks HD 21  
   Low 
frequency 
Left 
DLPFC 
5 Hz   10 2 wks   
   Sham     10 2 wks   
George 2010  
(50) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
92 3 wks HD 24  
   Sham rTMS     98 3 wks   
Grunhaus 2003  
(51) 
RCT 2 rTMS Left 
DLPFC 
10 Hz TRD DSM-
IV 
20 4 wks HD 17  
   ECT     20 4 wks   
Hansen 2004  
(52) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
6 7 wks HD 17  
   Sham TMS    DSM-
IV 
7 7 wks   
Hausmann 
2004  (53) 
RCT 2 Simultaneous 
bilateral 
rTMS 
Left and 
right 
DLPFC 
Left 20 Hz 
Right 1 Hz 
Depression DSM-
IV 
25 4 wks HD 21 Treatment group 
consisted of two 
groups of 
simultaneous bilateral 
(13) and Left DLPFC 
rTMS (12).  
   Sham rTMS     13 4 wks   
Hernandez-
Ribas 2013  
(54) 
RCT 2 High 
Frequency 
rTMS 
Left 
DLPFC 
15 Hz Depression DSM-
IV 
10 3 wks HD 21 Aim of the study is to 
identify brain imaging 
correlates of clinical 
response to rTMS    Sham rTMS     11 3 wks  
Herwig 2003  
(55) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
15 Hz Depression DSM-
IV 
13 2wks HD 21  
   Sham rTMS     12 2 wks   
Herwig 2007  
(56) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
62 3 wks HD 21  
   Sham rTMS     65 3 wks   
Holtzheimer III 
2004  (57) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
25 6 wks HD 17  
    Sham rTMS     25 6 wks   
Janicak 2002  
(58) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
13 4 wks HD 24  
   ECT     9 4 wks   
Janicak 2010  
(59) 
Non RCT 
trial 
1 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
99 24 wks HD 24 This is a non RCT 
extension study 
measuring durability 
of clinical benefit with 
rTMS. TMS in this 
study was for relapse  
Januel 2006  
(60) 
RCT 2 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz Depression DSM-
IV 
11 4 wks HD 17  
   Sham rTMS     16 4 wks HD 17  
Jhanwar 2011  
(61) 
Non RCT 
trial 
1 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
21 4 wks HD 17  
Kauffmann2004  
(62) 
RCT 2 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz TRD  
DSM-
IV 
7 10 
days 
HD 21  
   Sham rTMS     5 10 
days 
  
Keshtkar 2011  
(63) 
RCT 2 rTMS Left 
DLPFC 
NA TRD DSM-
IV 
40 10 
days 
HD 21  
   ECT Bilateral    33 3 wks   
Kito 2008  (64) Non RCT 
trial 
1 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz TRD DSM-
IV 
14 5 wks NA  
Kito 2011  (65) Non RCT 1 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz Depression DSM-
IV 
26 5 wks HD 21  
Klein 1999  
(66) 
RCT 2 Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz Depression DSM-
IV 
36 2 wks HD 17  
   Sham rTMS     34 2 wks   
Koerselamn 
2004  (67) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
26 14 wks HD 17  
   Sham rTMS     26 14 wks   
Loo 2006  (68) RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
19 6 wks HD 17  
   Sham rTMS     19 6 wks   
Maihofner 2005  
(69) 
Non RCT 1 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
8 10 
days 
HD 21  
Manes 2001  
(70) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
20 Hz TRD DSM-
IV 
10 12 
days 
NA  
   Sham rTMS     10 12 wks   
Martinot 2009  
(71) 
RCT 3 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz TRD DSM-
IVR 
18 10 day HD 21 Aim of the study is to 
explore the influence 
of prefrontal target 
region on the efficacy 
of rTMS 
   PET- guided 
rTMS 
Variable Variable   16 10 day HD 21 
   Sham rTMS     14 10 day   
Ming-li 2009  
(72) 
RCT 3 SEM-rTMS NA NA Depression DSM-
III 
57 10 
days 
HD 24 SEM: Sleep 
electroencephalogram 
    C-rTMS NA NA   55 10 
days 
 modulated; 
c:conventional 
   Sham rTMS NA NA   52 10 
days 
 
Moller 2006  
(73) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression ICD 
10 
7 5 days HD 17  
   Sham rTMS     3 5 days   
Mossiman 2004  
(74) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
15 10 
days 
HD 21  
   Sham rTMS     9 10 
days 
  
Myczkowski 
2012  (75) 
RCT 2 rTMS Left 
DLPFC 
5 Hz Depression DSM-
IV 
8 6 wks HD 17  
   Sham rTMS     6 6 wks   
Nahas 2001  
(76) 
RCT 3 High 
frequency 
rTMS 
Left 
DLPFC 
20 Hz Depression DSM-
IV 
9 2 wks NA Study explored the 
role of stimulation 
frequency and coil-
cortex distance    Low 
frequency 
rTMS 
Left 
DLPFC 
5 Hz   5 2 wks  
   Sham rTMS     9 2 wks   
O’Reardon 
2007  (77) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
155 6 wks HD 24 
HD 17 
 
   Sham rTMS     146 6 wks   
Padberg 1999  
(78) 
RCT 3 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz TRD DSM-
IV 
6 5 days HD 21  
   Low 
frequency 
rTMS 
Left 
DLPFC 
0.3 Hz   6 5 days   
   Sham rTMS     6 5 days   
            
           
            
Padberg 2002  
(79) 
Non RCT 1 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
33 2 wks HD 21 partial sleep 
deprivation at least 5 
days prior to rTMS; 
drug-free patients 
Price 2010  
(80) 
RCT 3 Combined   Depression DSM-
IV 
44 4 wks HD 21 Interactive rTMS 
applied individual 
stimuli in response to 
real time EEG 
 
   Standard 
rTMS 
Left 
DLPFC 
10 Hz   23 4 wks  
   Interactive 
rTMS 
Varied Varied   21 4 wks  
Rossini 2005  
(81) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
15 Hz Depression DSM-
IV 
50 5 wks HD 21 Study explored the 
adjunct response of 
rTMS to 
antidepressant Rx    Sham rTMS     49 5 wks  
Rossini 2010  
(82) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
15 Hz Depression DSM-
IV 
32 2 wks HD 21  
   Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz   42 2 wks   
  
 
Stern 2007  
(83) 
RCT 4 High 
frequency 
rTMS 
Left 
DLPFC 
10 Hz Depression DSM-
IV 
10 4 wks HD 21 Study compared the 
antidepressant effects 
of high and low 
frequency rTMS to 
DLPFC 
   Low 
frequency 
rTMS 
Left 
DLPFC 
1 Hz   10 4 wks  
   Low 
frequency 
rTMS 
Right 
DLPFC 
1 Hz   10 4 wks  
   Sham rTMS     15 4 wks   
Su 2005  (84) RCT 3 High 
frequency 
rTMS 
Left 
DLPFC 
20 Hz TRD DSM-
IV 
10 2 wks HD 21  
   Low 
frequency 
rTMS 
Left 
DLPFC 
5 Hz   10 2 wks   
   Sham rTMS     10 2 wks   
Triggs 1999  
(85) 
Non RCT 1 rTMS Left 
DLPFC 
NA Depression DSM-
IV 
10  2 wks NA  
Triggs 2010  
(86) 
RCT 4  Low 
frequency 
rTMS 
Right 
DLPFC 
5 Hz TRD DSM-
IV 
16 12 wks HD 24 Study compared right 
and left DLPF rTMS 
treatment in TRD 
   Low 
frequency 
rTMS 
Left 
DLPFC 
5 Hz   18 12 wks  
   Sham rTMS Right 
DLPFC 
   7 12 wks  
   Sham rTMS Left 
DLPFC 
   7 12 wks   
Turnier-Shea 
2006  (87) 
RCT 2 Daily rTMS Left 
DLPFC 
20 Hz Depression DSM-
IV 
8 12 wks HD 17 Spaced rTMS group 
received 5 treatments 
on spaced business 
days, half of other 
group 
   Spaced 
rTMS 
Left 
DLPFC 
20 Hz   8 12 wks  
Wang 2004  
(88) 
RCT 2 High 
Frequency 
rTMS 
Left 
DLPFC 
20 Hz Depression * 18 3 wks HD 17 *Chinese 
Psychological 
Disease Classification 
and Diagnosis 
Standard - Second 
Revision 
   ECT Bilateral    18 3 wks HD 17 
Zheng 2010  
(89) 
RCT 2 High 
frequency 
rTMS 
Left 
DLPFC 
15 Hz TRD DSM-
IV 
19 4 wks HD 17 Study explored 
increase in pre frontal 
myoinositol with high 
frequency rTMS 
   Sham rTMS     15 4 wks   
 Table 3: Results for sham-rTMS and rTMS in depression:  (first sham-controlled 
RCTs alone, then all trials combined) 
Number of included  
studies (treatment 
arms) 
Total sample  
size  
Combined mean  
difference (SD) * 
Percentage  
change mean  
(SD) 
 
CGI-I 
 
Sham-rTMS Depression (RCT alone) 
22 (22) 634 5.42 (4.18) 23.33 (16.51) 3·4 
rTMS Depression (RCT alone) 
22 (27) 743 8.8 (4.31) 35.63 (16.35) 2.9 
Sham-rTMS Depression (all trials) 
24 (24) 653 5·38 (4.15) 22.14 (16.55) 3.4 
rTMS Depression (all trials) 
38 (48) 1192 9.26 (3.99) 37.18 (15.13) 2·8 
* The HAMD combined mean differences are approximate because of the use of 3 different 
HAMD scales in the included studies 
 
 
 
 
 
 
 
 
 
 
 Table 4: Results for sham-rTMS and rTMS in TRD:  (first sham-controlled RCTs 
alone, then all trials combined) 
Number of included  
Studies (treatment 
arms) 
Total sample  
size  
Combined mean  
difference (SD) * 
Percentage  
change mean  
(SD) 
 
CGI-I 
 
Sham-rTMS Treatment Resistant Depression (RCT alone) 
10 (11) 120 6.18 (4.48) 25.04  (17.55) 3.3 
rTMS Treatment Resistant Depression (RCT alone) 
10 (15) 103 11.11 (2.60) 45.21 (10.94) 2.55 
Sham-rTMS Treatment Resistant Depression (all trials) 
11 (12) 153 5.65 (4.09) 23.03 (16.00) 3.4 
rTMS Treatment Resistant Depression (all trials) 
25 (41) 1138 11.43 (3.98) 47.77 (12.80) 2.4 
 
* The HAMD combined mean differences are approximate because of the use of 3 different 
HAMD scales in the included studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 CONSORT flow chart 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
960 records 
retrieved 
464 abstracts 
reviewed 
496 duplicates excluded 
187 full text 
articles requested 
277 abstracts excluded 
 160 non depression / TSD  
 45 non DLPFC rTMS 
 41 non RCT /open label, 
review 
 8 non English language 
 6 insufficient data 
 5 non-human 
 5 non adult 
 4 wrong format 
 1 duplicate patient group 
 1 conflicting data 
  
 2 other 
178 full text 
articles received 
9 articles unavailable 
60 articles  
initially included 
118 articles excluded 
 55 insufficient data 
 31 duplicate paper  
 12 non DLPFC rTMS 
 10 non RCT /open label, 
review 
 3 non English language 
 2 non depression / TRD  
 3 wrong format 
 2 duplicate patient group 
 1 non-human 
 
3 articles added 
from hand search 
63 articles  
finally included 
  
 
 
 
 
 
 
 
 
